TOKYO - Japan's health ministry panel on Thursday approved the commercialization of two regenerative medicine products prepared from iPS cells, the first of their kind in the world.
The two drugs, ReHeart developed by Cuorips Inc., a startup originating from the University of Osaka, and Amchepry by Sumitomo Pharma Co. and Racthera Inc., will be used for patients with severe heart failure and Parkinson's disease, respectively.
Log in or create a Free Membership
Account
Log in
or
Create accountFree Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
Related coverage:
